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DYRK1A promotes dopaminergic neuron survival in
the developing brain and in a mouse model of
Parkinson’s disease
MJ Barallobre1, C Perier2, J Bové2, A Laguna1,6, JM Delabar3, M Vila2,4,5 and ML Arbonés*,1
In the brain, programmed cell death (PCD) serves to adjust the numbers of the different types of neurons during development,
and its pathological reactivation in the adult leads to neurodegeneration. Dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 1A (DYRK1A) is a pleiotropic kinase involved in neural proliferation and cell death, and its role during brain growth is
evolutionarily conserved. Human DYRK1A lies in the Down syndrome critical region on chromosome 21, and heterozygous
mutations in the gene cause microcephaly and neurological dysfunction. The mouse model for DYRK1A haploinsufficiency (the
Dyrk1aþ / mouse) presents neuronal deficits in specific regions of the adult brain, including the substantia nigra (SN), although
the mechanisms underlying these pathogenic effects remain unclear. Here we study the effect of DYRK1A copy number variation
on dopaminergic cell homeostasis. We show that mesencephalic DA (mDA) neurons are generated in the embryo at normal rates
in the Dyrk1a haploinsufficient model and in a model (the mBACtgDyrk1a mouse) that carries three copies of Dyrk1a. We also
show that the number of mDA cells diminishes in postnatal Dyrk1aþ / mice and increases in mBACtgDyrk1a mice due to an
abnormal activity of the mitochondrial caspase9 (Casp9)-dependent apoptotic pathway during the main wave of PCD that affects
these neurons. In addition, we show that the cell death induced by 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), a toxin
that activates Casp9-dependent apoptosis in mDA neurons, is attenuated in adult mBACtgDyrk1a mice, leading to an
increased survival of SN DA neurons 21 days after MPTP intoxication. Finally, we present data indicating that Dyrk1a
phosphorylation of Casp9 at the Thr125 residue is the mechanism by which this kinase hinders both physiological and
pathological PCD in mDA neurons. These data provide new insight into the mechanisms that control cell death in brain DA
neurons and they show that deregulation of developmental apoptosis may contribute to the phenotype of patients with
imbalanced DYRK1A gene dosage.
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The total number of neurons in the brain, and ultimately the
size of this organ, depends both on the number of cells that
are produced during neurogenesis and the number of neurons
that die due to physiological programmed cell death (PCD).
Dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 1A (DYRK1A) regulates brain growth in a dose-
dependent manner,1 and indeed, loss-of-function mutations in
DYRK1A (minibrain in Drosophila melanogaster) cause
microcephaly and several neurological alterations in
humans,2–5 mice6 and flies.7 Accordingly, it has been
proposed that haploinsufficiency of DYRK1A is the cause of
the microcephaly and developmental delay associated to
partial monosomy of chromosome 21 involving DYRK1A.8
Moreover, triplication of the gene has been associated to
the developmental brain dysfunctions and age-associated
neurodegeneration observed in Down syndrome.9–11
Anatomical analysis of adult Dyrk1a mutant mice that model
human diseases involving an imbalance in DYRK1A gene
dosage (the Dyrk1aþ / mouse and the mBACtgDyrk1a
mouse, carrying one or three functional copies of
Dyrk1a, respectively) revealed a positive correlation
between Dyrk1a gene copy number, the overall size of the
brain and the number of neurons in specific regions.1
DYRK1A regulates several fundamental neurodevelopmental
processes, including proliferation, neuron differentiation and
PCD.12 Overexpression of DYRK1A in neural precursors
attenuates proliferation and promotes the differentiation of
neurons in different model systems.13–15 Conversely, treat-
ment of neural progenitors with DYRK1A kinase inhibitors
increases proliferation.15 Although these data are consistent
with some of the defects in cellularity identified in specific brain
regions of Dyrk1a gene copy number mutants, they cannot
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explain the severe microcephaly evident in mice and humans
carrying one functional copy of DYRK1A, or the overall
macrocephaly in the mBACtgDyrk1a model carrying three
Dyrk1a alleles.1,5 Thus, deregulation of other DYRK1A
functions might also contribute to the defects in brain
cellularity in these Dyrk1a gene copy number mutants, such
as those described in retinal neurons that restrain develop-
mental PCD.16
Dopaminergic (DA) neurons in the substantia nigra (SN)
and ventral tegmental area (VTA) have an important role in
controlling fine motor actions, as well as in motivation and
reward behaviours, and their loss is associated with Parkin-
son’s disease.17 In aged Dyrk1aþ / mice the SN is smaller
and contains fewer DA neurons than in wild-type mice.18
These mutant animals are hypoactive, with altered gait
dynamics, and as these defects are evident preweaning and
in young animals,6,18,19 as well as in children with hetero-
zygous mutations in DYRK1A,3–5 they might arise during
development.
To provide insight into the aetiology of the neurological
phenotype caused by DYRK1A haploinsufficiency, here we
studied the development of mesencephalic DA (mDA)
neurons in Dyrk1aþ / and mBACtgDyrk1a mouse models.
The results obtained show that Dyrk1a copy number variation
does not affect the generation of DA neurons, but rather it
modifies the number of these neurons that undergo physio-
logical PCD due to an inhibitory effect of the Dyrk1a kinase on
the apoptotic activity of caspase9 (Casp9), the initiator
caspase in the mitochondrial-dependent apoptotic pathway.20
Thus, deregulation of Casp9-dependent PCD during devel-
opment may contribute to the brain size defects observed in
aneuploidies involving DYRK1A.
As inappropriate re-activation of the mitochondrial-
dependent apoptotic pathway in mature mDA neurons
contributes to the neurodegeneration associated with
Parkinson’s disease,21 we used the mBACtgDyrk1a
mouse model to assess whether basal Dyrk1a-dependent
inhibition of Casp9 apoptotic activity could restrain the
neurodegeneration induced in vivo by the parkinsonian
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). Our results show that the apoptotic response to the
toxin in mBACtgDyrk1a mice is significantly attenuated,
leading to an increase in the number of SN pars compacta
DA neurons that resist the pathological insult.
Results
Dyrk1a promotes the survival of mDA neurons during
the physiological period of PCD. DA neurons in the SN
and VTA originate from progenitors in the ventral neuroe-
pithelium and they subsequently migrate radially to the
mantle zone where they differentiate. The distribution of the
neurons can be tracked by following that of tyrosine
hydroxylase (TH), a marker of DA neurons that is initially
detected in mice at around embryonic day (E)1022,23 (see
scheme in Figure 1a). As the distribution of Dyrk1a protein in
the developing ventral mesencephalon is unknown, we used
a Dyrk1a-specific antibody16,24 to analyse the expression of
the protein in this region at two developmental stages: at
E12.5, during the phase of DA neurogenesis, and at
postnatal day (P)0, when neurogenesis has been completed
and the excess DA neurons generated are removed by
PCD25 (see scheme in Figure 2a). In the embryo, Dyrk1a
protein accumulates in the cytoplasm of post-mitotic cells
within the intermediate zone and in cells that already express
TH in the mantle zone (Figure 1b). By P0, Dyrk1a was also
evident in differentiating neurons that express TH in the SN
(Figure 1c) and VTA (data not shown). This distribution is
compatible with Dyrk1a participating in the embryonic and
postnatal development of mDA neurons, supporting the
possibility that the deficit in SN DA neurons observed
previously in 2-year-old Dyrk1aþ / mice arises during
development.18
To test this possibility, we quantified the number of cells
expressing TH in the mesencephalon of Dyrk1aþ /þ and
Dyrk1aþ / embryos at E14.5, soon after the period of DA
neurogenesis in the ventral mesencephalon (Figure 2a). The
number and distribution of THþ neurons was similar in both
Figure 1 Expression of the Dyrk1a protein in the mouse ventral mesencephalon during development. (a) Schematic sagittal view of the mouse embryonic neural
tube (E11.5 to E14.5) indicating the site of DA neurogenesis in the mesencephalon (yellow area) and the position occupied by DA progenitors (blue), immature DA neurons
(TH cell in yellow) and mature DA neurons (THþ cells in red) in a transverse section at the level indicated by the black rectangle. (b and c) Confocal images showing
co-localization of Dyrk1a (D1a in green) and TH (red) in the ventral mesencephalon of wild-type E12.5 embryos (b) and P0 mice (c). HIND, hindbrain; IZ, intermediate zone;
MES, mesencephalon; MZ, mantle zone; TEL, telencephalon; VZ, ventricular zone. Bar¼ 50mm
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these genotypes (Figure 2b), indicating that mDA neurons in
Dyrk1aþ / embryos are produced normally. Moreover, these
neurons seemed to differentiate correctly in the Dyrk1aþ /
mutants, given that they expressed nuclear-orphan-receptor-1
(Nurr1), a transcription factor that is required for the
maintenance of DA neurons,23 and that they innervated the
striatum at E16.5, the correct stage of development26
(Supplementary Figure S1). Thus, the generation and
specification of mDA neurons appear to be unaltered in
Dyrk1aþ / mice.
The number of mesencephalic THþ neurons in
Dyrk1aþ / mutants remained normal at P0 (VTAþSN:
Dyrk1aþ /þ ¼ 18 877±2364 and Dyrk1aþ / ¼ 18 434±697;
P¼ 0.86; n¼ 4). However, when we assessed the number of
these neurons in the mesencephalon of Dyrk1aþ /þ and
Dyrk1aþ / mice at P7, subsequent to the major programmed
wave of DA neuron cell death (Figure 2a), fewer THþ cells
were detected in Dyrk1a mutant mice (37% less) than in
wild-type mice (Figure 2c). Despite the PCD that occurs, the
number of mesencephalic THþ neurons increases during
postnatal development,27 and indeed, THþ cells were more
abundant in young (8-week-old) Dyrk1aþ /þ mice than at P7.
A similar age-dependent increase in THþ neurons was
observed in 8-week-old Dyrk1aþ / mice, although there
were fewer of these neurons in mutant animals (Figures 2c
and d). Importantly, the reduction in THþ cells at this age
(38%) was similar to the reduction of SN DA neurons reported
previously in aged Dyrk1aþ / mice.18 In both young
Dyrk1aþ /þ and Dyrk1aþ / mice the mesencephalic neurons
that expressed the dopamine active transporter (DAT) also
contained TH (Supplementary Figure S2). Moreover, we did
not find differences between genotypes in the proportion of
Nissl-stained neurons that contained TH (Dyrk1aþ /þ :
SN¼ 0.43±0.03; VTA¼ 0.43±0.03 and Dyrk1aþ / :
SN¼ 0.46±0.01; VTA¼ 0.46±0.04; n¼ 4), indicating that
Dyrk1a haploinsufficiency does not affect TH expression, but
rather that it reduces the number of DA cells expressing this
enzyme. Together, these results suggest that the loss of DA
neurons in Dyrk1aþ / mice occurs during the major wave of
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Figure 2 THþ cell counts in the mesencephalon of Dyrk1a mutant mice at different developmental stages. (a) Scheme indicating the period of DA neuron production
(green) and of PCD (purple) in the mouse ventral mesencephalon.27 (b–g) Representative mesencephalic sections stained for TH from Dyrk1aþ /þ (D1aþ /þ ) and Dyrk1aþ /
(D1aþ / ) brains (b–d) and from wild-type (WT) and mBACtgDyrk1a (BACD1a) brains (e–g) at the developmental stages indicated, and total number of THþ cells in the
whole ventral mesencephalon (VTAþ SN; (b and e), or in the VTA and the SN alone (c, d, f and g). Histogram values are the mean±S.E.M. *Pr0.05; **Pr0.01;
***Pr0.001; n¼ 3 in (b, e and f); n¼ 4 in (c and g); n¼ 5 in (d). Bar¼ 100mm (b, c, e and f), 300mm (d and g)
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To further assess how Dyrk1a influences DA neuron
development, we performed a similar analysis in the
mBACtgDyrk1a model that expresses three copies of the
mouse Dyrk1a gene.1 As observed in the Dyrk1aþ / model,
the number of THþ cells in the mesencephalon of mBACtg-
Dyrk1a mice was normal at E14.5 (Figure 2e) but not at P7,
when there were significantly more DA neurons in the mutant
(Figure 2f). However, and in contrast to what happens in the
Dyrk1aþ / mouse, young mBACtgDyrk1a mice had normal
numbers of DA neurons in both the SN and VTA (Figure 2g).
The second wave of PCD in mDA neurons takes place during
the second and third week of life25 (Figure 2a), when
synaptogenesis is maximal in the developing striatum.28
Therefore, the excess of DA neurons in P7 mBACtgDyrk1a
mice may be offset by the exacerbated wave of cell death
during this period, possibly due to limited neurotrophic
support of target neurons.27 This is supported by the fact
that P21 mBACtgDyrk1a and wild-type animals have similar
numbers of SN THþ neurons (8588±813 versus 8388±659;
P¼ 0.85; n¼ 4).
Overall, our results indicate that changes in Dyrk1a
dosage do not affect the generation and differentiation
of mouse mDA neurons but they modify the number
of these neurons that die during the main wave of DA
PCD. Such cell death is increased in the loss-of-function
mutant and decreased in the gain-of-function mutant.
This protective effect of Dyrk1a might be mediated through
its kinase activity, as harmine, an inhibitor of the enzymatic
activity of DYRK1A,9 induces a dose-dependent reduction
of THþ neurons in primary mesencephalic cell cultures
(Figure 3a).
Dyrk1a promotes the survival of mDA neurons during
development by restricting the activity of the intrinsic
apoptotic pathway. The first wave of post-natal PCD in
rodents involves the activation of the intrinsic (mitochondrial-
dependent) cell death pathway.25 In this pathway, the
release of cytochrome c from the mitochondria to the cytosol
that is induced by apoptotic stimuli leads to Casp9 cleavage,
which promotes cell death by activating downstream execu-
tioner caspases.20,29 There is evidence that phosphorylation
of the Thr125 residue in Casp9 prevents its cleavage in these
circumstances and, hence, the subsequent activation of the
intrinsic apoptotic pathway.30 DYRK1A is known to phos-
phorylate Casp9 at Thr125 (Laguna et al.16 and Seifert
et al.31) and this phosphorylation is crucial to protect
differentiating retinal neurons from mitochondrial-dependent
cell death.16 To determine whether phosphorylation of Casp9
by Dyrk1a is involved in the protection of DA neurons in the
developing ventral mesencephalon, we used a phospho-site-
specific antibody and quantified the amount of Thr125-
phosphorylated Casp9 in the ventral mesencephalon of
Dyrk1aþ / , mBACtgDyrk1a and wild-type littermate mice
during the main wave of developmental DA neuron cell
death, by P2 (Figure 2a). In mesencephalic extracts derived
from Dyrk1aþ / animals, there was significantly less Dyrk1a
protein, which was correlated with a significant decrease in
















































































































Figure 3 Effect of the DYRK1A inhibitor harmine on DA neuron survival and the levels of phosphorylated Casp9 in the developing ventral mesencephalon of Dyrk1a
mutant mice. (a) Representative images of E12 mesencephalic cells after 4 days in culture (DIV) stained for TH (red), and the percentage of THþ cells in cultures maintained
in the presence or absence (NT) of harmine. (b) Scheme indicating the effect of Dyrk1a phosphorylation on the intrinsic cell death pathway. (c and d) Representative western
blottings and their quantifications showing the levels of Dyrk1a (D1a) normalized to the amount of Vinculin (Vinc), and the proportion of Casp9 that is Thr125 phosphorylated
(P(Thr125)) in total mesencephalic extracts from P2 Dyrk1aþ /þ (D1aþ /þ ) and Dyrk1aþ / (D1aþ / ) mice (c), and from wild-type (WT) and mBACtgDyrk1a (BACD1a)
mice (d). Mito, mitochondria. Histogram values are the mean±S.E.M. *Pr0.05; **Pr0.01 (n¼ 3 in (a); n¼ 4 in (c and d))
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Conversely, there was an increase in the amount of Dyrk1a
protein in mBACtgDyrk1a extracts that was correlated with
an increase in the pool of phosphorylated Casp9 (Figure 3d).
We assessed the activity of the Casp9-dependent apoptotic
pathway in the mesencephalon of postnatal Dyrk1a mutant
mice, studying the distribution of the active (cleaved) forms of
Casp9 and its downstream executioner caspase3 (Casp3) in
the TH-immunostained mesencephalic region of Dyrk1aþ / ,
mBACtgDyrk1a and wild-type littermate mice. In wild-type
animals, active Casp9 and Casp3 immunostaining can be
observed in apoptotic THþ cells at P0 (Figure 4a). As
expected, there were significantly more apoptotic cells
expressing active Casp9 in Dyrk1aþ / mice (Figure 4b)
and fewer in mBACtgDyrk1a mice (Figure 4c). Consistently,
there were more apoptotic cells expressing active Casp3 in
Dyrk1aþ / animals (Figure 4d) and fewer in mBACtgDyrk1a
animals (Figure 4e). Together, these results indicate that the
defects in DA cellularity observed in P7 Dyrk1a mutant mice
arise from the aberrant activity of Casp9-mediated apoptosis,
and that Thr125 phosphorylation of Casp9 by Dyrk1a can
regulate cell death in these neurons.
Dyrk1a overexpression promotes the survival of SN pars
compacta DA neurons in the MPTP-induced mouse
model of Parkinson disease. There is evidence that the
intrinsic apoptotic pathway participates in the neurodegen-
eration of SN pars compacta DA neurons in Parkinson’s
disease. Indeed, dying neurons in post-mortem Parkinson’s
tissue display morphological characteristics of apoptosis,
including the activation of Casp9 and Casp3, cell shrinkage,
chromatin condensation and DNA fragmentation.21,32 More-
over, Dyrk1a protein is still found in the cytoplasm of THþ
neurons of the SN pars compacta after development
(Figure 5a, upper panels). Taking into account the pro-
survival action of Dyrk1a on developing DA neurons reported
here (Figure 4), we hypothesized that Dyrk1a could restrain
the neurodegenerative response in a parkinsonian context.
To test this possibility we assessed the effect of the
parkinsonian neurotoxin MPTP33 on adult mBACtgDyrk1a
mice, which still contain relatively large amounts of Dyrk1a
protein and Thr125-phosphorylated Casp9 in the ventral
mesencephalon (Figure 5b), while establishing a normal






































































Figure 4 Numbers of apoptotic cells in the ventral mesencephalon of newborn Dyrk1a mutant mice. (a) Confocal images from brain sections of a P0 wild-type (WT) mouse
showing TH expression in mesencephalic neurons that contain active Casp9 (A-Casp9) or active Casp3 (A-Casp3), and total numbers of A-Casp9þ cells (b and c) and
A-Casp3þ cells (d and e) in the ventral mesencephalon (VTAþSN) of P0 Dyrk1aþ /þ (D1aþ /þ ) and Dyrk1aþ / (D1aþ / ) mice (b and d), and of wild-type (WT) and
mBACtgDyrk1a (BACD1a) mice (c and e). Histogram values are the mean±S.E.M. *Pr0.05; **Pr0.01; ***Pr0.001 (n¼ 4 in (b and d); n¼ 3 in (c and e))
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Given the importance of the mitochondria in the pathogen-
esis of Parkinson’s disease32 and the multiple functions of
DYRK1A,34 we assessed the status of the mitochondria in
these mice. The relative levels of mitochondrial components,
including cytochrome c oxidase complex subunits, were
similar in the mesencephalon of adult mBACtgDyrk1a and
wild-type mice (Supplementary Figure S3). Likewise, there
were no differences in oxygen consumption in isolated brain
mitochondria from either wild-type or mBACtgDyrk1a mice
(Supplementary Figure S4a). With regard to the sensitivity of
brain mitochondria to 1-methyl-4-phenylpyridinum ion, the
active MPTP metabolite, similar inhibition of ADP-stimulated
oxygen consumption supported by complex I substrate
glutamate/malate (respiration, state 3) was observed in
mBACtgDyrk1a and wild-type mitochondria. In addition, both
genotypes produced similar amounts of reactive oxygen
species and displayed similar levels of mitochondria antiox-
idant proteins (Supplementary Figures S4b and c). Together,
these data indicate that mitochondrial biogenesis and function
is well preserved in mBACtgDyrk1a mice, and that the
inhibitory action of the parkinsonian toxin MPTP on the
mitochondria is not affected in these animals.
We then challenged mBACtgDyrk1a mice and their


















































Figure 5 Expression of Dyrk1a and the levels of phosphorylated Casp9 in the ventral mesencephalon of adult mBACtgDyrk1a (BACD1a) mice. (a) Confocal images
showing a similar Dyrk1a distribution in the SN of 8-week-old (8W) wild-type (WT) and BACD1a mice. Bar¼ 100mm. (b) Representative western blottings and their
quantifications showing the levels of Dyrk1a (D1a) normalized to the amount of Vinculin (Vinc), and the proportion of Casp9 that is Thr125 phosphorylated (P(Thr125)) in total
mesencephalic extracts prepared from 12- to 16-week-old WT and BACD1a littermates. Histogram values are the mean±S.E.M. *Pr0.05 (n¼ 5)
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(30 mg/kg/day for five consecutive days: see schedule in
Figure 6a), a protocol known to kill SN pars compacta DA
neurons by activating mitochondrial-dependent apoptotic
pathways in a time-dependent manner, peaking 4 days after
the last MPTP injection.35–37 Basal levels of both Dyrk1a
protein and phosphorylated Casp9 in these animals did not
change after MPTP treatment (Supplementary Figure S5).
Yet, at the peak of MPTP-induced apoptotic cell death,
pyknotic cells and cells expressing active Casp9 were clearly
detected in wild-type and mBACtgDyrk1a mice (Figure 6b).
However, there were significantly fewer apoptotic active
Casp9þ cells in mBACtgDyrk1a mice administered MPTP
than in the equivalent wild-type mice (Figure 6b). Indeed,
mBACtgDyrk1a mice exhibited a marked attenuation of
MPTP-induced SN pars compacta DA cell death by day 21
post MPTP (Figure 6c), once the MPTP-induced lesion had
been stabilized.36
Together, these results show that moderate over-
expression of Dyrk1a in mature mDA neurons attenuates
the apoptotic response induced by MPTP intoxication,
leading to an enhanced survival of SNpc DA neurons in
this model.
Discussion
In this work we show that DYRK1A regulates Casp9-mediated
cell death in mouse mDA neurons in vivo and in two different
context: during the main wave of developmental PCD in these
neurons and in the SN pars compacta of adult animals that
have been challenged with the parkinsonian neurotoxin
MPTP. In both contexts, the amount of Dyrk1a protein in the
ventral mesencephalon is directly correlated to the levels of
Casp9 phosphorylated at the inhibitory Thr125, and it is
inversely correlated to the number of DA neurons that die by
the intrinsic (Casp9-mediated) cell death pathway. There is
evidence that basal DYRK1A phosphorylation of pro-Casp9 at
Thr125 restrains Casp9-dependent apoptosis in the develop-
ing retina16 and in cultured cells under hyperosmotic stress.38
DYRK1A is synthesized as a constitutively active kinase39
and, therefore, it is assumed that its kinase activity is directly
related to the amount of protein.9,34 Our data suggest that
Dyrk1a is the kinase that phosphorylates Casp9 in the
developing and adult mesencephalon, and that this phos-
phorylation is not modified by MPTP intoxication. Accordingly,
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Figure 6 MPTP intoxication of adult mBACtgDyrk1a mice. (a) Schedule of MPTP intoxication employed in experiments in (b and c). (b) Dual immunohistochemistry for
TH and active Casp9 (A-Casp9) in the SN pars compacta of a wild-type (WT) animal 4 days after MPTP intoxication, showing a pyknotic cell (arrowhead) and an active
Casp9þ (black) cell (arrow) expressing TH (brown), and the total numbers of active Casp9þ cells quantified in the SN pars compacta of WT and mBACtgDyrk1a
(BACD1a) animals injected with saline (Sal.) or MPTP. (c) Representative images showing THþ cells in the SN pars compacta of saline- or MPTP-treated WT and
BACD1a animals 21 days after MPTP intoxication, and the quantification of the total THþ cells in this region for the four experimental groups. Histogram values are the
mean±S.E.M. N, not significant (P40.05); *Pr0.05; **Pr0.01; ****Pr0.0001 (n¼ 3; p-ANOVA¼ 0.001 in (b) and n¼ 5; p-ANOVA¼ 0.01 in (c)). Bar¼ 100 mm (b
and c)
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brain DA neurons establishes the levels of inhibitory Thr125
phosphorylation of Casp9, which in turn defines the threshold
of the apoptotic stimulus that is needed to irreversibly activate
the caspase cell death cascade, either during development or
in a pathological neurodegenerative condition in the adult.
The altered size of certain regions in the brain of Dyrk1aþ /
and mBACtgDyrk1a mutant mice is prominent in some cases
(i.e., the hippocampus and the ventral thalamic postero lateral
and postero medial nuclei) but not in others (i.e., the cerebral
cortex). The prominently affected regions are smaller and with
less neurons in the Dyrk1aþ / model, and they are larger and
with more neurons in the mBACtgDyrk1a model.1 Therefore,
deregulation of Casp9-dependent developmental cell death
could contribute to the defects in cellularity in these brain
regions. Nonetheless, alterations in the cytoarchitecture of the
brain are complex in Dyrk1a mutants, with regions showing
higher densities of neurons in the Dyrk1aþ / haploinsuffi-
cient model and lower densities in the mBACtgDyrk1a triploid
model.1,6 These observations indicate that in addition to PCD,
other developmental processes that regulate neural progenitor
proliferation and differentiation must also be disturbed in specific
domains of the developing brain in Dyrk1a mutants.12
The excess of DA neurons observed in the mBACtgDyrk1a
overexpression model after the main postnatal wave of PCD
was not longer evident at P21. As the second wave of DA
neuron PCD in the mouse takes place during the second and
third week of life,25 this observation raises the possibility that
the second wave of cell death was exacerbated in mBACtg-
Dyrk1a mice as an attempt to counterbalance the excess of
DA neurons and adjust the number of projection neurons to
their targets. During the second wave of PCD, at P14, the
levels of Thr125-phosphorylated Casp9 in the ventral mesen-
cephalon of mBACtgDyrk1a mice are still higher than in the
wild types (Supplementary Figure 6a), and consequently
mBACtgDyrk1a mutants at this stage have less cells
expressing active Casp9 (Supplementary Figure 6b). How-
ever, and contrary to what we have observed in newborn
mBACtgDyrk1a mice, the number of apoptotic cells expres-
sing active Casp3 was slightly increased in P14 mBACtg-
Dyrk1a mice (Supplementary Figure 6b). Together, these
observations suggest that the second wave of DA neuron
PCD involves, in addition to the Casp9-mediated pathway,
another caspase-dependent cell death pathway. Indeed,
there is evidence that cell death of DA differentiating neurons
induced by deprivation of growth factors is mediated by a non-
classical mitochondria-independent cell death pathway that
involves the activation of several caspases and the death
receptor-caspase8 pathway.40 The existence of such
mechanisms may explain why the defects in brain size and
cellularity are more severe in Dyrk1aþ / mice than in
mBACtgDyrk1a mice.1
SN pars compacta DA neurons in adult mBACtgDyrk1a
mice were protected against MPTP-induced neurodegeneration,
suggesting that therapies aimed at preventing Casp9 cleavage
could ameliorate or delay neurodegeneration in Parkinson’s
disease. This concept is supported by studies showing a
certain degree of protection against MPTP intoxication
through the administration of the pan-caspase inhibitor
Q-VD-OPH,41 the expression in transgenic mice of the general
caspase inhibitor protein baculoviral p35,42 or by adenoviral
gene transfer of the X-chromosome-linked inhibitor of
apoptosis.43 Although neuroprotection in these studies was
analysed shortly after MPTP administration, the results shown
here indicate that inhibition of Casp9 cleavage can protect DA
cells from MPTP-induced cell death over longer periods of
time. Unfortunately, the beneficial effect of caspase inhibitors
in Parkinson’s disease has been challenged by the negative
results of clinical trials into the use of caspase inhibitors,44
which could be due to the difficulties to design clinical trials
relevant to neuroprotection, not only given the heterogeneity of
the disease but also due to the absence of in vivo indicators of
neuronal dysfunction to monitor the possible effects of the drug.
In addition to Casp9, DYRK1A was shown to phosphorylate
a-synuclein in vitro and acute overexpression of both
DYRK1A and a-synuclein enhances the formation of intracel-
lular inclusions in immortalized hippocampal H19-7 cells,
which is associated to a decreased survival of these cells.45
The neuroprotection offered against MPTP and the fact that
6-month-old mBACtgDyrk1a mice have a normal complement
of DA neurons indicate that triplication of the mouse Dyrk1a
gene alone does not compromise the viability of SN pars
compacta DA neurons, but instead it protects these cells
against pathological insult. Based on the effect of DYRK1A on
a-synuclein phosphorylation, it has been suggested that
DYRK1A might favour the formation of Lewy bodies in
Parkinson’s disease and in Down syndrome.10 However, the
possible effect of trisomy 21 in Lewy body formation has been
challenged by clinical studies showing that parkinsonian signs
are less evident in Down syndrome individuals than in patients
with advanced Alzheimer’s disease46 and also by pathological
observations revealing the absence of Lewy bodies in the SN
of adults with Down syndrome.47 Although the neuroprotec-
tion offered by Dyrk1a described here could differ in a context
of complete trisomy 21 in humans, the results of this work
raise concern about possible deleterious effects of excessive
therapeutic DYRK1A inhibition to improve cognitive perfor-
mance in adults with Down syndrome.9
In summary, our data shows that normal levels of DYRK1A
kinase activity are necessary for the survival of mDA neurons
during development and in the adult brain after re-activation of
the intrinsic cell death pathway in a pathological situation.
These results could be of interest in the context of Parkinson’s
disease and challenge the general association of DYRK1A
overexpression with neurodegenerative diseases. In addition,
our data provide insights into the aetiology of the micro-
cephaly and motor gait dysfunctions in children with hetero-
zygous mutations in the DYRK1A gene.
Materials and Methods
Unless otherwise stated, all materials were obtained from Sigma-Aldrich (Tres
Cantos, Madrid, Spain).
Animals. The generation of the Dyrk1aþ / mouse and the mBACtgDyrk1a
mouse was described previously.1,6 Both Dyrk1a mutants were maintained on
their original genetic backgrounds and genotyped by PCR:1,6 Dyrk1aþ / mice
by repeated backcrossing of Dyrk1aþ / males to C57BL/6Jx129S2/SvHsd
F1 females (Harlan Laboratories, Bicester, UK) and mBACtgDyrk1a mice by
repeated backcrossing of transgenic males to C57BL6/J females (Charles River
Laboratories, L’Arbresle, France). Fertility of Dyrk1aþ / mice is compromised
when the mutants were crossed with C57BL6/J mice, which precluded having both
Dyrk1a mutants on the same genetic background. The day of the vaginal plug was
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defined as E0, and the day of birth was defined as P0. We used wild-type
littermates as controls and males for the studies in adult animals, except for the
respiratory and reactive oxygen species production assays that were performed on
both males and females.
All the experimental procedures were carried out in accordance with the
European Union guidelines (Directive 2010/63/EU) and the followed protocols were
approved by the ethics committees of the Parc de Recerca Biomèdica de Barcelona
(PRBB) and Research Institute-University Hospital Vall d’Hebron (VHIR).
MPTP treatment. To induce sub-acute MPTP toxicity, 14- to 24-week-old
wild-type or mBACtgDyrk1a male mice received one daily i.p. injection of MPTP-
HCl (30 mg/kg of free base) on five consecutive days, as described previously.48
MPTP-treated mice and saline-injected control animals were then killed at the time
after the last injection indicated (Figure 6a).
Tissue processing for histology and immunostaining. To obtain
embryonic and P0 tissue, whole heads were fixed by immersion in 4%
paraformaldehyde (PFA) for 24 h at 4 1C, cryoprotected with 30% sucrose in PBS,
embedded in Tissue-Tek O.C.T. (Sakura Finetek Europe B.V., Alphen aan den
Rijn, The Netherlands), frozen in isopentane at  30 1C and sectioned on a
cryostat. Cryosections (16 mm) were collected on Starfrost precoated slides
(Knittel Glasser, Braunschweig, Germany) and distributed serially. Postnatal
and adult (2- to 6-month-old) mice were deeply anaesthetized in a CO2
chamber and transcardially perfused with 4% PFA. The brains were removed,
post-fixed and cryoprotected as indicated above, and cryotome (40 mm) sections
were then distributed serially. For Dyrk1a immunostaining, the post-fixed brains
were sectioned directly on a vibratome (40 mm).
Immunostainings. Immunohistochemistry on brain sections was performed
following the avidin–biotin–peroxidase method (Vectastain ABC kit, Vector Labs,
Burlingame, CA, USA). Briefly, sections were incubated in PBS at 37 1C for 15 min
and then endogenous peroxidase activity was blocked with 3% H2O2 and 10%
methanol in PBS for 30 min at room temperature (RT). The sections were then
blocked for 2 h at RT in PBS containing 0.2% Triton-X100 (Merck, Madrid, Spain)
and 10% fetal bovine serum (FBS; Life Technologies S.A., Alcobendas, Spain)
and probed for 12 to 48 h at 4 1C with the primary antibodies diluted in Antibody
Buffer (AB: PBS containing 0.2% Triton-X100 and 5% FBS). After washing, the
sections were incubated with the corresponding biotinylated secondary antibody
diluted in AB, washed and incubated with an avidin–biotin–peroxidase solution
according to the manufacturer’s indications. Peroxidase activity was visualized
with 0.03% diaminobenzidine (DAB) and 0.003% H2O2. All samples were
counterstained with Nissl (0.1% Cresyl violet acetate) to visualize non-
immunopositive cells.
For dual immunohistochemistry with a-active-Casp3 or a-active-Casp9 and a-TH
antibodies using the avidin–biotin–peroxidase method, we performed a sequential
labelling. Cryosections were first incubated with a-active-Casp3 or a-active-Casp9,
and antibody binding was detected using the appropriate biotinylated secondary
antibody and the biotin–avidin complex (Vectastain, Vector Labs), which was
visualized with 0.03% DAB and 0.2% nickel ammonium sulphate. Sections were
then treated for 30 min with 10% methanol and 3% H2O2 in PBS to inhibit the
residual peroxidase activity and they were incubated with the TH antibody. The
following steps were performed as described before.
Secondary Alexa Fluor-conjugated antibodies (Life Technologies S.A.) were
used for dual immunofluorescence and Hoechst was used to stain the nuclei
following the same protocol as for immunohistochemistry but without blocking
endogenous peroxidase activity.
A complete list of the antibodies used in immunohistochemistry and
immunofluorescence can be found in Supplementary Table 1.
Cell counts on tissue sections. The THþ cells were quantified in brain
sections counterstained with Nissl using stereological methods. Sections from
animals of different genotypes were processed in parallel to avoid daily variations
in immunostaining. The THþ cells in E14.5 tissue was estimated by counting the
immunopositive cells in dissectors that covered 25% of the reference area in every
four serially distributed sections of the ventral mesencephalon. The THþ cell
number in the SN and VTA of P7, P21 and adult samples was counted in
dissectors covering 15% of the reference area in every three serial sections. The
proportion of THþ cells relative to Nissl stained neurons was quantified by
counting both types of cells in dissectors covering the 10% of the reference area
every six serial sections. The coefficient of error tolerated was o10% and the
dissectors with the upper right corner outside the sampled area were not included
in the total number of dissectors. The nuclei that contacted one of the two
predetermined adjacent sides of the rectangular dissector frame were not included
in the count. The number of active Casp3þ and active Casp9þ cells were
calculated by counting the immunopositive cells in the entire region labelled with
the anti-TH staining in one of every six serially distributed sections at P0, and in
one every three serially distributed sections from the P14 mice and the adult saline
and MPTP-treated animals.
Mesencephalic primary cultures. Mouse primary cultures enriched
in DA neurons were prepared as described elsewhere.49 Briefly, the
ventral mesencephalon was isolated from E12.5 C57BL6/J embryos and the
mechanically dissociated cells were seeded on cover slides coated with
poly-D-lysine and laminin, and cultured in the presence of a mixture of
F12/DMEM media (Life Technologies S.A.) supplemented with 0.25% bovine
serum albumin, N1 additives and antibiotics (Life Technologies S.A.). After 4 days
in culture, the cells were treated with harmine (harmine-HCl 1–10mM dissolved in
H2O MilliQ; TCI Europe N. V., Zwijndrecht, Belgium) or vehicle (H2O MilliQ)
overnight, fixed and immunostained. The coverslips were sampled systematically,
counting the number of THþ cells in at least 12 fields per coverslip and in
two coverslips per condition. Cell counts were performed in three independent
cultures.
Western blotting. Protein extracts (60 mg) were resolved by SDS-PAGE
and transferred onto a nitrocellulose membrane (Hybond-ECL, Amersham
Biosciences, Little Chalfont, UK) that was probed with antibodies whose binding
was detected by infrared fluorescence using the LI-COR Odyssey IR Imaging
System V3.0 (LI-COR Biosciences, Cambridge, UK). A complete list of the
antibodies used to probe western blottings is provided in Supplementary Table 2.
Statistical analysis. The data were analysed by the two-tailed Student’s
t-test or by ANOVA followed by a two-tailed Student’s t-test, and they are
presented as the mean±S.E.M. Any differences were considered significant at
P-valuesr0.05. The n indicated in the figure legend refers to the minimum
number of biological samples (embryos, mice or cell cultures) of the same
condition (genotype) that were analysed in each experiment: *Pr0.05;
**Pr0.01; ***Pr0.001; ****Pr0.0001.
The methodology followed to isolate brain mitochondria and to perform the
experiments with isolated mitochondria are indicated in the Supplementary Material
and Methods.
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